CompletedNCT00191295
Atomoxetine compared with placebo for childhood ADHD
About this title
Read the official source — NCT00191295This study evaluated the safety and effectiveness of Atomoxetine for people with ADHD.
Medication studyAges 6–18Japan
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Atomoxetine for people with ADHD.
Who was this study for?
Listed age limits: 6 years to 18 years.
- Listed locations
- Aichi and 23 more locationsSee all locations and recruitment
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateFebruary 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 240
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- Japan
- Age range
- From 6 Years to 18 Years
- Official registry ID
- NCT00191295
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges of Atomoxetine Hydrochloride in Child Outpatients With Attention-Deficit/Hyperactivity Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Aichi · Chiba · Fukui
21 more locations
- Fukuoka
- Hokkaido
- Hyōgo
- Ibaraki
- Ishikawa
- Kanagawa
- Kumamoto
- Mie
- Miyagi
- Nagano
- Nara
- Okayama
- Osaka
- Saga
- Shiga
- Shizuoka
- Tochigi
- Tokushima
- Tokyo
- Toyama
- Wakayama
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Atomoxetine for people with ADHD.
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including Atomoxetine and Placebo.
Who was this study for?
Listed age limits: 6 years to 18 years.
